ProKidney [PROK] vs Vertex [VRTX] Detailed Stock Comparison

ProKidney

Vertex
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: ProKidney wins in 6 metrics, Vertex wins in 11 metrics, with 0 ties. Vertex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
Metric | ProKidney | Vertex | Better |
---|---|---|---|
P/E Ratio (TTM) | -4.42 | 28.68 | ProKidney |
Price-to-Book Ratio | 1.06 | 6.02 | ProKidney |
Debt-to-Equity Ratio | 1.30 | 8.89 | ProKidney |
PEG Ratio | 0.24 | -0.22 | Vertex |
EV/EBITDA | -8.38 | 20.53 | ProKidney |
Profit Margin (TTM) | 0.00% | 31.86% | Vertex |
Operating Margin (TTM) | -17,967.87% | 38.93% | Vertex |
EBITDA Margin (TTM) | N/A | 38.93% | N/A |
Return on Equity | -40.52% | 22.77% | Vertex |
Return on Assets (TTM) | -25.30% | 13.09% | Vertex |
Free Cash Flow (TTM) | $-155.86M | $-978.00M | ProKidney |
Dividend Yield | 305.81% | N/A | N/A |
1-Year Return | 61.18% | -11.42% | ProKidney |
Price-to-Sales Ratio (TTM) | 1,552.38 | 9.06 | Vertex |
Enterprise Value | $1.43B | $98.55B | Vertex |
EV/Revenue Ratio | 2,707.64 | 8.63 | Vertex |
Gross Profit Margin (TTM) | N/A | 86.25% | N/A |
Revenue per Share (TTM) | $0 | $44 | Vertex |
Earnings per Share (Diluted) | $-0.56 | $14.06 | Vertex |
Beta (Stock Volatility) | 1.78 | 0.43 | Vertex |
ProKidney vs Vertex Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
Stock | 1D | 1W | 1M | 3M | 6M | YTD |
---|---|---|---|---|---|---|
ProKidney | -1.44% | 10.04% | 16.10% | 328.13% | 285.92% | 58.38% |
Vertex | -1.36% | 4.55% | 1.68% | -12.25% | -16.68% | -0.61% |
Long-term Returns
Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
---|---|---|---|---|---|---|
ProKidney | 61.18% | -71.04% | -72.74% | -72.74% | -72.74% | -72.74% |
Vertex | -11.42% | 36.61% | 49.40% | 266.64% | 1,042.17% | 1,773.20% |
News Based Sentiment: ProKidney vs Vertex
ProKidney
News based Sentiment: MIXED
ProKidney experienced significant price fluctuations and conflicting analyst ratings during October 2025. While speculative buying drove up the stock price, insider selling and a downgraded rating from Bank of America create a mixed investment picture. The lack of fundamental news driving these movements adds to the uncertainty.
Vertex
News based Sentiment: POSITIVE
Vertex Pharmaceuticals delivered strong financial results in Q2 2025 and raised its full-year guidance, coupled with positive developments in its pipeline and favorable analyst coverage. This combination of factors indicates a positive trajectory for the company and strengthens the investment case.
Performance & Financial Health Analysis: ProKidney vs Vertex
Metric | PROK | VRTX |
---|---|---|
Market Information | ||
Market Cap | $806.33M | $103.40B |
Market Cap Category | Small cap | Large cap |
10 Day Avg. Volume | 1,296,280 | 1,835,420 |
90 Day Avg. Volume | 1,987,337 | 1,652,450 |
Last Close | $2.74 | $403.30 |
52 Week Range | $0.46 - $7.13 | $362.50 - $519.88 |
% from 52W High | -61.57% | -22.42% |
All-Time High | $14.19 (Mar 13, 2023) | $519.88 (Nov 04, 2024) |
% from All-Time High | -80.69% | -22.42% |
Growth Metrics | ||
Quarterly Revenue Growth | -0.04% | 0.12% |
Quarterly Earnings Growth | N/A | 0.12% |
Financial Health | ||
Profit Margin (TTM) | 0.00% | 0.32% |
Operating Margin (TTM) | -179.68% | 0.39% |
Return on Equity (TTM) | -0.41% | 0.23% |
Debt to Equity (MRQ) | 1.30 | 8.89 |
Cash & Liquidity | ||
Book Value per Share (MRQ) | $-7.51 | $67.02 |
Cash per Share (MRQ) | $2.18 | $24.90 |
Operating Cash Flow (TTM) | $-114,420,000 | $3.85B |
Levered Free Cash Flow (TTM) | $-112,575,248 | $2.91B |
Dividends | ||
Last 12-Month Dividend Yield | 305.81% | N/A |
Last 12-Month Dividend | $2.63 | N/A |
Valuation & Enterprise Metrics Analysis: ProKidney vs Vertex
Metric | PROK | VRTX |
---|---|---|
Price Ratios | ||
P/E Ratio (TTM) | -4.42 | 28.68 |
Forward P/E | -5.45 | 21.49 |
PEG Ratio | 0.24 | -0.22 |
Price to Sales (TTM) | 1,552.38 | 9.06 |
Price to Book (MRQ) | 1.06 | 6.02 |
Market Capitalization | ||
Market Capitalization | $806.33M | $103.40B |
Enterprise Value | $1.43B | $98.55B |
Enterprise Value Metrics | ||
Enterprise to Revenue | 2,707.64 | 8.63 |
Enterprise to EBITDA | -8.38 | 20.53 |
Risk & Other Metrics | ||
Beta | 1.78 | 0.43 |
Book Value per Share (MRQ) | $-7.51 | $67.02 |
Financial Statements Comparison: ProKidney vs Vertex
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
Metric (MRQ) | PROK | VRTX |
---|---|---|
Revenue/Sales | $230,000 | $2.96B |
Cost of Goods Sold | N/A | $407.50M |
Gross Profit | N/A | $2.56B |
Research & Development | $27.26M | $978.40M |
Operating Income (EBIT) | $-41.39M | $1.15B |
EBITDA | $-35.76M | $1.34B |
Pre-Tax Income | $-37.36M | $1.28B |
Income Tax | $591,000 | $250.10M |
Net Income (Profit) | $-37.95M | $1.03B |
Balance Sheet & Liquidity Metrics (MRQ)
Metric (MRQ) | PROK | VRTX |
---|---|---|
Cash & Equivalents | $97.81M | $4.67B |
Total Current Assets | $359.66M | $10.01B |
Total Current Liabilities | $32.81M | $3.78B |
Long-Term Debt | $2.51M | $1.65B |
Total Shareholders Equity | $369.98M | $16.50B |
Retained Earnings | $-1.22B | $10.25B |
Property, Plant & Equipment | $3.07M | $2.63B |
Cash Flow Statement Comparison (MRQ)
Metric (MRQ) | PROK | VRTX |
---|---|---|
Operating Cash Flow | $-35.14M | $404.90M |
Capital Expenditures | $-1.14M | $-40.70M |
Free Cash Flow | $-30.73M | $778.20M |
Debt Repayment | $-12,000 | $-1.30M |
Common Stock Repurchase | N/A | $-696.60M |
Short Interest & Institutional Ownership Analysis
Metric | PROK | VRTX |
---|---|---|
Shares Short | 10.12M | 4.05M |
Short Ratio | 4.23 | 2.83 |
Short % of Float | 0.11% | 0.02% |
Average Daily Volume (10 Day) | 1,296,280 | 1,835,420 |
Average Daily Volume (90 Day) | 1,987,337 | 1,652,450 |
Shares Outstanding | 128.05M | 256.94M |
Float Shares | 86.72M | 255.58M |
% Held by Insiders | 0.27% | 0.00% |
% Held by Institutions | 0.30% | 0.98% |
Dividend Analysis & Yield Comparison: ProKidney vs Vertex
Metric | PROK | VRTX |
---|---|---|
Last 12-Month Dividend | $2.63 | N/A |
Last 12-Month Dividend Yield | 305.81% | N/A |
3-Year Avg Annual Dividend | $3.15 | N/A |
3-Year Avg Dividend Yield | 36.48% | N/A |
3-Year Total Dividends | $9.44 | N/A |
Ex-Dividend Date | Feb 14, 2025 | N/A |